A. Winogrodzka et al., [I-123]FP-CIT SPECT is a useful method to monitor the rate of dopaminergicdegeneration in early-stage Parkinson's disease, J NEURAL TR, 108(8-9), 2001, pp. 1011-1019
We investigated the applicability [I-123]FP-CIT SPECT for the assessment of
the rate of dopaminergic degeneration in PD.
Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were exa
mined twice, a mean of 12 months apart. The mean annual change in the ratio
of specific to nonspecific [I-123]FP-CIT binding to the striatum was used
as the outcome measure. The mean annual decrease in striatal [I-123]FP-CIT
binding ratios was found to be about 8% (of the baseline mean).
In order to demonstrate a significant effect (p < 0.05) of putative neuropr
otective agent with 0.80 power and 50% of predicted protection within 2 yea
rs, 36 patients are required in each group, when the effects are measured b
y means of changes in [I-123]FP-CIT binding ratios in whole striatum.
Our findings indicate that [I-123]FP-CIT SPECT seems to be a useful tool to
investigate the progression of dopaminergic degeneration in PD and may pro
vide an objective method of measuring the effectiveness of neuroprotective
therapies.